Epidemiology, patient profile, and health care resource use for hepatitis C in Italy

Figures & data

Figure 1 Flowchart of cohort definition

Abbreviations: HCV, hepatitis C virus; LHU, local health unit.

Table 1 Baseline demographic and clinical characteristics of the study population (N=7,550)

Characteristics
Age (years)
Mean ± SD	57.6 ± 16.4
18–29	335 (4.4)
30–49	2,307 (30.5)
50–69	2,846 (37.7)
70+	2,062 (27.3)
Gender
Male	4,308 (57.1)
Charlson comorbidity index, mean (SD)	1.1 ± 1.4
0	3,218 (42.6)
1–2	3,364 (44.5)
3–4	749 (9.9)
5+	219 (2.9)
Coinfections with HBV or HIV	88 (1.2)
HIV	33 (0.4)
HBV	55 (0.7)
History of hospitalization
Cardiovascular events	9 (0.1)
Cirrhosis	612 (8.1)
HCC	52 (0.7)
Liver transplantation	4 (0.1)
Neuropsychological events	8 (0.1)
HCV treatment type during 6 months pre-ID
peg-IFN with or without RBV	289 (3.8)
PI with or without peg-IFN	14 (0.2)
Untreated patients	7,247 (96.0)
Other treatments
Antianemic drugs	385 (5.1)
Dermatological drugs	185 (2.5)

Note: Data shown as n (%) or mean ± SD.

Abbreviations: SD, standard deviation; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; peg-IFN, peg-interferon; RBV, ribavirin; PI, protease inhibitors; ID, index date.

Figure 2 Treatment patterns during the follow-up period

Abbreviations: peg-IFN, peg-interferon; RBV, ribavirin; PI, protease inhibitors.

Figure 3 Annual health care costs (mean ± standard deviation) for the management of HCV patients, based on resource consumption during the follow-up period

Abbreviation: HCV, hepatitis C virus